Description: RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Home Page: renovorx.com
RNXT Technical Analysis
4546 El Camino Real
Los Altos,
CA
94022
United States
Phone:
650 284 4433
Officers
| Name | Title |
|---|---|
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board & Chief Medical Officer |
| Mr. Shaun R. Bagai | CEO & Director |
| Mr. James M. Ahlers | Chief Financial Officer |
| Ms. Angela Gill Nelms | Chief Operating Officer |
| Mr. Ronald B. Kocak CPA | VP & Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1661 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |